We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Mersana Therapeutics Inc (MRSN) COM USD0.0001

Sell:$1.61 Buy:$1.62 Change: $0.09 (5.88%)
NASDAQ:1.35%
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$1.61
Buy:$1.62
Change: $0.09 (5.88%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$1.61
Buy:$1.62
Change: $0.09 (5.88%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.

Contact details

Address:
840 Memorial Dr
CAMBRIDGE
02139-3789
United States
Telephone:
+1 (617) 4980020
Website:
https://www.mersana.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MRSN
ISIN:
US59045L1061
Market cap:
$187.35 million
Shares in issue:
123.53 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Martin Huber
    President, Chief Executive Officer, Director
  • Brian Deschuytner
    Chief Financial Officer, Chief Operating Officer, Senior Vice President
  • Timothy Lowinger
    Senior Vice President, Chief Science and Technology Officer
  • Mohan Bala
    Senior Vice President, Chief Development Officer
  • Alejandra Carvajal
    Senior Vice President, Chief Legal Officer
  • Tushar Misra
    Senior Vice President, Chief Manufacturing Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.